{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:15:35Z","timestamp":1763968535576,"version":"3.37.3"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11899-023-00706-7","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:02:06Z","timestamp":1690257726000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia\/Lymphoma"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam S.","family":"DuVall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Wesevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"14","key":"706_CR1","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548\u201359. Practice changing publication on AYA ALL from an adult cooperative group.","journal-title":"Blood"},{"issue":"8","key":"706_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077\u201384.","journal-title":"Blood"},{"issue":"28","key":"706_CR3","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, et al. Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(28):3282\u201393. Practice changing trial for young people with T ALL from the pediatric collaborative group.","journal-title":"J Clin Oncol"},{"issue":"2","key":"706_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood-2014-05-576470","volume":"125","author":"D Jing","year":"2015","unstructured":"Jing D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125(2):273\u201383.","journal-title":"Blood"},{"issue":"12","key":"706_CR5","doi-asserted-by":"publisher","first-page":"e1002200","DOI":"10.1371\/journal.pmed.1002200","volume":"13","author":"Y Li","year":"2016","unstructured":"Li Y, et al. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLOS Med. 2016;13(12):e1002200.","journal-title":"PLoS Med."},{"issue":"5","key":"706_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1084\/jem.20040789","volume":"200","author":"JT Barata","year":"2004","unstructured":"Barata JT, et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med. 2004;200(5):659\u201369.","journal-title":"J Exp Med."},{"issue":"12","key":"706_CR7","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41375-021-01291-5","volume":"35","author":"JCG van der Zwet","year":"2021","unstructured":"van der Zwet JCG, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia. 2021;35(12):3394\u2013405.","journal-title":"Leukemia"},{"key":"706_CR8","doi-asserted-by":"crossref","unstructured":"Dillon M, et al. Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers (Basel). 2021;13(20).","DOI":"10.3390\/cancers13205059"},{"issue":"17","key":"706_CR9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/bloodadvances.2018021063","volume":"2","author":"D Ribeiro","year":"2018","unstructured":"Ribeiro D, et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2018;2(17):2199\u2013213.","journal-title":"Blood Adv."},{"issue":"5","key":"706_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2159-8290.CD-17-0583","volume":"8","author":"CE de Bock","year":"2018","unstructured":"de Bock CE, et al. HOXA9 cooperates with activated JAK\/STAT signaling to drive leukemia development. Cancer Discov. 2018;8(5):616\u201331.","journal-title":"Cancer Discov."},{"issue":"5","key":"706_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bcp.2012.09.018","volume":"85","author":"C Blanco-Aparicio","year":"2013","unstructured":"Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013;85(5):629\u201343.","journal-title":"Biochem Pharmacol."},{"issue":"3","key":"706_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.biocel.2005.10.010","volume":"38","author":"M Bachmann","year":"2006","unstructured":"Bachmann M, et al. The oncogenic serine\/threonine kinase Pim-1 directly phosphorylates and activates the G2\/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006;38(3):430\u201343.","journal-title":"Int J Biochem Cell Biol."},{"issue":"12","key":"706_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood.2019000553","volume":"138","author":"A Silva","year":"2021","unstructured":"Silva A, et al. Overexpression of wild-type IL-7R\u03b1 promotes T-cell acute lymphoblastic leukemia\/lymphoma. Blood. 2021;138(12):1040\u201352.","journal-title":"Blood"},{"issue":"19","key":"706_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2019003880","volume":"135","author":"R De Smedt","year":"2020","unstructured":"De Smedt R, et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020;135(19):1685\u201395.","journal-title":"Blood"},{"issue":"1","key":"706_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","volume":"5","author":"S Luszczak","year":"2020","unstructured":"Luszczak S, et al. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduct Targeted Ther. 2020;5(1):7.","journal-title":"Signal Transduct Targeted Ther."},{"issue":"3","key":"706_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/sj.leu.2404101","volume":"20","author":"MR Mansour","year":"2006","unstructured":"Mansour MR, et al. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia. 2006;20(3):537\u20139.","journal-title":"Leukemia"},{"issue":"15","key":"706_CR17","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1101\/gad.1450406","volume":"20","author":"AP Weng","year":"2006","unstructured":"Weng AP, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia\/lymphoma. Genes Dev. 2006;20(15):2096\u2013109.","journal-title":"Genes Dev."},{"issue":"7270","key":"706_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature08543","volume":"462","author":"RE Moellering","year":"2009","unstructured":"Moellering RE, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462(7270):182\u20138.","journal-title":"Nature"},{"issue":"1","key":"706_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm.1900","volume":"15","author":"PJ Real","year":"2009","unstructured":"Real PJ, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50\u20138.","journal-title":"Nat Med."},{"issue":"3","key":"706_CR20","doi-asserted-by":"publisher","first-page":"G490","DOI":"10.1152\/ajpgi.90393.2008","volume":"296","author":"H Zheng","year":"2009","unstructured":"Zheng H, et al. KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G490\u20138.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"21","key":"706_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1182\/blood.V124.21.968.968","volume":"124","author":"PA Zweidler-McKay","year":"2014","unstructured":"Zweidler-McKay PA, et al. The safety and activity of BMS-906024, a gamma secretase inhibitor (GSI) with anti-Notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL): initial results of a phase 1 trial. Blood. 2014;124(21):968\u20138.","journal-title":"Blood"},{"issue":"1","key":"706_CR22","doi-asserted-by":"publisher","first-page":"a000539","DOI":"10.1101\/mcs.a000539","volume":"1","author":"B Knoechel","year":"2015","unstructured":"Knoechel B, et al. Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the \u03b3-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud. 2015;1(1):a000539.","journal-title":"Cold Spring Harb Mol Case Stud."},{"issue":"3","key":"706_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cncr.33188","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, et al. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer. 2021;127(3):372\u201380.","journal-title":"Cancer"},{"issue":"8","key":"706_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O'Neil","year":"2007","unstructured":"O'Neil J, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813\u201324.","journal-title":"J Exp Med."},{"issue":"4","key":"706_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel B, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364\u201370.","journal-title":"Nat Genet."},{"issue":"8","key":"706_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1211\u20138. Article that includes a detailed description of genetic changes seen in T ALL.","journal-title":"Nat Genet."},{"issue":"6","key":"706_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1535-6108(03)00301-5","volume":"4","author":"E Sicinska","year":"2003","unstructured":"Sicinska E, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell. 2003;4(6):451\u201361.","journal-title":"Cancer Cell."},{"issue":"4","key":"706_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","volume":"22","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438\u201351.","journal-title":"Cancer Cell."},{"issue":"4","key":"706_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","volume":"23","author":"Y Pikman","year":"2017","unstructured":"Pikman Y, et al. Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23(4):1012\u201324.","journal-title":"Clin Cancer Res."},{"issue":"7511","key":"706_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616\u201320.","journal-title":"Nature"},{"issue":"6215","key":"706_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","volume":"346","author":"MR Mansour","year":"2014","unstructured":"Mansour MR, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346(6215):1373\u20137.","journal-title":"Science"},{"issue":"4","key":"706_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26(4):922\u201334.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"706_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson CM, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018;14(2):163\u201370.","journal-title":"Nat Chem Biol."},{"issue":"3","key":"706_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393\u2013403.","journal-title":"Mol Cell."},{"issue":"9","key":"706_CR35","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074\u201387.","journal-title":"Cancer Discov."},{"issue":"4","key":"706_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"Supplement_1","key":"706_CR37","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1182\/blood-2019-129988","volume":"134","author":"N Jain","year":"2019","unstructured":"Jain N, et al. A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed\/refractory acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):3867\u20137. An excellent preliminary study in older adults with combination chemotherapy that will likely drive future randomized trials.","journal-title":"Blood"},{"key":"706_CR38","unstructured":"Pullarkat VA, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u20131453. Early phase study demonstrating effectiveness of BCL-2\/BCL-XL combination in relapsed ALL."},{"issue":"7","key":"706_CR39","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/leu.2012.31","volume":"26","author":"A Vilas-Zornoza","year":"2012","unstructured":"Vilas-Zornoza A, et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia. 2012;26(7):1517\u201326.","journal-title":"Leukemia"},{"key":"706_CR40","doi-asserted-by":"publisher","first-page":"106707","DOI":"10.1016\/j.leukres.2021.106707","volume":"110","author":"HE Carraway","year":"2021","unstructured":"Carraway HE, et al. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk Res. 2021;110:106707.","journal-title":"Leuk Res."},{"key":"706_CR41","doi-asserted-by":"crossref","unstructured":"Touzart A, et al. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Sci Transl Med. 2021;13(595).","DOI":"10.1126\/scitranslmed.abc4834"},{"issue":"7","key":"706_CR42","doi-asserted-by":"publisher","first-page":"e991","DOI":"10.1097\/MPH.0000000000002050","volume":"43","author":"MU Baig","year":"2021","unstructured":"Baig MU, et al. Venetoclax and decitabine in pediatric refractory T-cell lymphoblastic lymphoma. J Pediatr Hematol Oncol. 2021;43(7):e991\u20136.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"706_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, et al. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14(3):246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"706_CR44","first-page":"6092646","volume":"2018","author":"LT Rahmat","year":"2018","unstructured":"Rahmat LT, et al. Venetoclax in combination with decitabine for relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case Rep Hematol. 2018;2018:6092646.","journal-title":"Case Rep Hematol."},{"key":"706_CR45","doi-asserted-by":"crossref","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2).","DOI":"10.3390\/cancers12020265"},{"key":"706_CR46","doi-asserted-by":"crossref","unstructured":"Lato MW, et al. The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(9).","DOI":"10.3390\/ijms22094502"},{"issue":"2","key":"706_CR47","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"186","author":"TM Horton","year":"2019","unstructured":"Horton TM, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019;186(2):274\u201385.","journal-title":"Br J Haematol."},{"key":"706_CR48","unstructured":"Teachey DT, et al. Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022:Jco2102678. Initial evidence of potential utility of proteasome inhibition in T ALL."},{"issue":"3","key":"706_CR49","doi-asserted-by":"publisher","first-page":"e28062","DOI":"10.1002\/pbc.28062","volume":"67","author":"KJ August","year":"2020","unstructured":"August KJ, et al. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2020;67(3):e28062.","journal-title":"Pediatr Blood Cancer."},{"key":"706_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2021.2018582","volume":"63","author":"P Amrein","year":"2022","unstructured":"Amrein P, et al. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Leuk Lymphoma. 2022;63:1\u20138.","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"706_CR51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","volume":"100","author":"C Vicente","year":"2015","unstructured":"Vicente C, et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015;100(10):1301\u201310.","journal-title":"Haematologica"},{"issue":"9","key":"706_CR52","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi T, et al. The genetics and molecular biology of T-ALL. Blood. 2017;129(9):1113\u201323.","journal-title":"Blood"},{"issue":"7380","key":"706_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157\u201363.","journal-title":"Nature"},{"issue":"11","key":"706_CR54","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, et al. Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125(11):1759\u201367.","journal-title":"Blood"},{"issue":"12","key":"706_CR55","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/leu.2017.136","volume":"31","author":"C Delgado-Martin","year":"2017","unstructured":"Delgado-Martin C, et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568\u201376.","journal-title":"Leukemia"},{"issue":"6","key":"706_CR56","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.leu.2403357","volume":"18","author":"KE Barber","year":"2004","unstructured":"Barber KE, et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia. 2004;18(6):1153\u20136.","journal-title":"Leukemia"},{"issue":"10","key":"706_CR57","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ng1425","volume":"36","author":"C Graux","year":"2004","unstructured":"Graux C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36(10):1084\u20139.","journal-title":"Nat Genet"},{"issue":"6","key":"706_CR58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/leu.2008.80","volume":"22","author":"A Quint\u00e1s-Cardama","year":"2008","unstructured":"Quint\u00e1s-Cardama A, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008;22(6):1117\u201324.","journal-title":"Leukemia"},{"issue":"2","key":"706_CR59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ccell.2018.07.007","volume":"34","author":"M Vanden Bempt","year":"2018","unstructured":"Vanden Bempt M, et al. Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1\/TLX1-positive T cell acute lymphoblastic leukemia. Cancer Cell. 2018;34(2):271\u2013285.e7.","journal-title":"Cancer Cell."},{"issue":"9","key":"706_CR60","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1038\/bcj.2017.87","volume":"7","author":"S Laukkanen","year":"2017","unstructured":"Laukkanen S, et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 2017;7(9):e604.","journal-title":"Blood Cancer J"},{"issue":"11","key":"706_CR61","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26\u201337.","journal-title":"Blood"},{"issue":"3","key":"706_CR62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/leu.2008.318","volume":"23","author":"W Deenik","year":"2009","unstructured":"Deenik W, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(3):627\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"706_CR63","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41467-022-28682-1","volume":"13","author":"V Cordo\u2019","year":"2022","unstructured":"Cordo\u2019 V, et al. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nat Comm. 2022;13(1):1048.","journal-title":"Nat Comm"},{"issue":"1","key":"706_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bjh.17310","volume":"194","author":"R Pocock","year":"2021","unstructured":"Pocock R, et al. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia. Br J Haematol. 2021;194(1):28\u201343.","journal-title":"Br J Haematol."},{"issue":"11","key":"706_CR65","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1158\/0008-5472.CAN-05-0751","volume":"65","author":"A Palamarchuk","year":"2005","unstructured":"Palamarchuk A, et al. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res. 2005;65(11):4515\u20139.","journal-title":"Cancer Res."},{"issue":"3","key":"706_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez A, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647\u201350.","journal-title":"Blood"},{"issue":"6","key":"706_CR67","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","volume":"24","author":"E Piovan","year":"2013","unstructured":"Piovan E, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24(6):766\u201376.","journal-title":"Cancer Cell."},{"issue":"2","key":"706_CR68","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/hon.2831","volume":"39","author":"D Kong","year":"2021","unstructured":"Kong D, et al. Growth inhibition and suppression of the mTOR and Wnt\/\u03b2-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion. Hematol Oncol. 2021;39(2):222\u201330.","journal-title":"Hematol Oncol."},{"issue":"12","key":"706_CR69","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, et al. A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2015;21(12):2704\u201314.","journal-title":"Clin Cancer Res."},{"issue":"9","key":"706_CR70","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995\u20139. Potential preclinical evidence to incorporate daratumumab in future T ALL clinical trials.","journal-title":"Blood"},{"issue":"3","key":"706_CR71","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(3):e100\u20133.","journal-title":"Haematologica"},{"issue":"5","key":"706_CR72","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/cam4.4478","volume":"11","author":"N Boissel","year":"2022","unstructured":"Boissel N, et al. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: phase 2 study. Cancer Med. 2022;11(5):1292\u20138.","journal-title":"Cancer Med."},{"issue":"13","key":"706_CR73","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra CL, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res. 2019;25(13):3921\u201333.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"706_CR74","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41571-021-00556-3","volume":"18","author":"DT Teachey","year":"2021","unstructured":"Teachey DT, Hunger SP. Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. Nat Rev Clin Oncol. 2021;18(11):677\u20138.","journal-title":"Nat Rev Clin Oncol."},{"issue":"30","key":"706_CR75","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39(30):3340\u201351.","journal-title":"J Clin Oncol."},{"issue":"1","key":"706_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Engineering CAR-T cells. Biomark Res. 2017;5(1):22.","journal-title":"Biomark Res."},{"issue":"5","key":"706_CR77","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med."},{"issue":"1","key":"706_CR78","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","volume":"12","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit? Stem Cell Res Ther. 2021;12(1):527.","journal-title":"Stem Cell Res Ther."},{"issue":"21","key":"706_CR79","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez D, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133(21):2291\u2013304.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00706-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:18:35Z","timestamp":1702030715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00706-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00706-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"3 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"DuVall: speaker for CE Concepts; Wesevich: no conflicts of interests or competing interests; Larson: consultant or advisor to AbbVie, Amgen, Ariad\/Takeda, Astellas, Celgene\/BMS, Curis, CVS\/Caremark, Epizyme, Immunogen, Jazz Pharmaceuticals, Kling Biotherapeutics, MedPace, MorphoSys, Novartis, and Servier and has received clinical research support to his institution from Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven\/Gilead, Novartis, and Rafael Pharmaceuticals and royalties from UpToDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}